Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241 The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]
Financing led by new investor TCGX, alongside Goldman Sachs Alternatives, Avoro Ventures, and venBio Funding will support and accelerate development of next-generation multivalent respiratory virus vaccines using proprietary Molecular Clamp technology Commenced Phase I clinical study of bivalent vaccine targeting both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) London, UK, 23 September 2024: Vicebio […]
RSV drug candidates with the highest probability of success prioritised 20 December 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus […]
